We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

A Breakthrough Solution for AAV Manufacturing Challenges

Credit: iStock

Despite the success of AAV for gene therapies and vaccines, many challenges still exist within AAV manufacturing. To ensure the safety and efficacy of a therapeutic, it is crucial to accurately determine the percentage of capsids that carry the gene of interest.   

Traditional methods to determine the ratio of empty and full (E/F) AAV particles are costly and lack high-throughput capabilities and compatibility with crude samples.

This whitepaper outlines the use of a novel biolayer interferometry (BLI) assay for the evaluation of % full AAV capsid in test samples representing different stages of process development, which is revolutionizing the determination of the E/F ratio for real-time decision-making at any process step. 

Download this whitepaper to discover:

  • A cost-effective solution that can provide accurate E/F measurements throughout the AAV manufacturing process
  • Capsid packaging analytics, compatible with crude samples
  • How to obtain reliable, semi-quantitative results in various buffer conditions
Sponsored by

Download Your Whitepaper for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.